These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 4076530

  • 21. Pharmacological preconditioning of ischaemia.
    Laghi Pasini F, Capecchi PL, Acciavatti A, Petri S, de Lalla A, Cati G, Colafati M, Di Perri T.
    Clin Hemorheol Microcirc; 1997; 17(1):73-84. PubMed ID: 9181761
    [Abstract] [Full Text] [Related]

  • 22. [Acute affect of buflomedil hydrochloride (bufedil) on transcutaneously measured oxygen pressures in patients with peripheral arterial occlusive disease].
    Lemke R, Klaus D.
    Vasa; 1984; 13(2):171-4. PubMed ID: 6741240
    [No Abstract] [Full Text] [Related]

  • 23. Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review.
    Spitzer S, Bach R, Schieffer H.
    Int Angiol; 1992; 11(3):204-10. PubMed ID: 1460355
    [Abstract] [Full Text] [Related]

  • 24. [Can vasomotion be modified by vasoactive substances or hemodilution?].
    Tischler R, Decrinis M, Skursky-Roller R.
    Acta Med Austriaca; 1994; 21(5):133-6. PubMed ID: 7709711
    [Abstract] [Full Text] [Related]

  • 25. Effect of buflomedil chlorhydrate on local oxygen delivery in peripheral vascular disease.
    Mannarino E, Pasqualini L, Maragoni G, Orlandi U.
    Angiology; 1989 Jun; 40(6):559-62. PubMed ID: 2719340
    [Abstract] [Full Text] [Related]

  • 26. Blood flow properties and walking performance in chronic arterial occlusive disease.
    Angelkort B, Spürk P, Habbaba A, Mähder M.
    Angiology; 1985 May; 36(5):285-92. PubMed ID: 3896044
    [Abstract] [Full Text] [Related]

  • 27. [Buflomedil in arterial occlusive disease. Results of a controlled study].
    Trübestein G, Balzer K, Bisler H, Klüken N, Mahfoud Y, Müller-Wiefel H, Unkel B, Ziegler W.
    Dtsch Med Wochenschr; 1982 Dec 24; 107(51-52):1957-61. PubMed ID: 6756854
    [No Abstract] [Full Text] [Related]

  • 28. Haemodynamic and haemorheological effects of buflomedil in patients with peripheral occlusive arterial disease.
    Perego MA, Sergio G, Espureo M, Francisci A, Artale F.
    Curr Med Res Opin; 1982 Dec 24; 8(3):178-87. PubMed ID: 7128189
    [Abstract] [Full Text] [Related]

  • 29. [Are beta-blockers generally contraindicated in patients with peripheral arterial occlusive disease?].
    Schweizer J, Kaulen R, Altmann E, Nierade A, Nanning T.
    Z Kardiol; 1996 Mar 24; 85(3):193-7. PubMed ID: 8659199
    [Abstract] [Full Text] [Related]

  • 30. A review of long-term safety data with buflomedil.
    Bachand RT, Dubourg AY.
    J Int Med Res; 1990 Mar 24; 18(3):245-52. PubMed ID: 2193838
    [Abstract] [Full Text] [Related]

  • 31. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
    Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA.
    Int Angiol; 2001 Dec 24; 20(4):337-44. PubMed ID: 11782701
    [Abstract] [Full Text] [Related]

  • 32. [Effects of the administration of buflomedil-hydrochloride on the arterial circulation of the legs in patients with obliterative arteriopathies].
    Tallarida G, Baldoni F, Peruzzi G, Raimondi G, Grimaldi I, Visigalli G, Gristina S, Massaro M, De Martinis L, Sangiorgi M.
    Cardiologia; 1983 Aug 24; 28(8):651-60. PubMed ID: 6687209
    [No Abstract] [Full Text] [Related]

  • 33. Improvement of microcirculation abnormalities in sickle cell patients upon buflomedil treatment.
    Bachir D, Maurel A, Beuzard Y, Razavian M, Kraiem A, Portos JL, Galacteros F.
    Microvasc Res; 1993 Nov 24; 46(3):359-73. PubMed ID: 8121319
    [Abstract] [Full Text] [Related]

  • 34. [Effects of buflomedil on peripheral arteriopathies. An open clinical study].
    Longo FN, Potortì F, Urbano O, Perroni GB.
    Minerva Cardioangiol; 1988 May 24; 36(5):249-52. PubMed ID: 3059229
    [No Abstract] [Full Text] [Related]

  • 35. [Scintigraphy with thallium-201 in the evaluation of vasoactive treatment in subjects with obliterative arteriopathies of the lower limbs].
    Licata G, Parrinello G, Scaglione R, Indovina A, Pinto A, Capuana G, Mazzola G.
    Cardiologia; 1987 Nov 24; 32(11):1449-56. PubMed ID: 2965976
    [No Abstract] [Full Text] [Related]

  • 36. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease.
    Milio G, Cospite V, Cospite M.
    Minerva Cardioangiol; 2003 Jun 24; 51(3):311-6. PubMed ID: 12867883
    [Abstract] [Full Text] [Related]

  • 37. Effects of buflomedil on skin blood flow in patients with type 2 diabetes mellitus without overt micro- or macroangiopathy.
    Tsantilas D, Hatzitolios AI, Tziomalos K, Karamitsos D, Papadimitriou D.
    Int Angiol; 2011 Apr 24; 30(2):164-71. PubMed ID: 21427654
    [Abstract] [Full Text] [Related]

  • 38. [Effects of buflomedil hydrochloride on the rheological properties of the blood in chronic cerebrovascular diseases].
    Lombardini R, Ciuffetti G, Paltriccia R, Scarponi AM, Savastano V, Palazzetti D, Mercuri M, Parnetti L.
    Ric Clin Lab; 1989 Apr 24; 19 Suppl 1():117-9. PubMed ID: 2629069
    [No Abstract] [Full Text] [Related]

  • 39. Comparative evaluation of the effectiveness of buflomedil and pentoxifylline in patients with arterial occlusive disease.
    Trübestein G, Trübestein R, Duong QD.
    Angiology; 1981 Oct 24; 32(10):705-10. PubMed ID: 7034591
    [Abstract] [Full Text] [Related]

  • 40. [Comparison of the effectiveness of intra-arterial and intravenous administration of buflomedil in patients with intermittent claudication].
    Diehm C, Eckstein M, Hübsch-Müller C.
    Vasa; 1989 Oct 24; 18(1):40-7. PubMed ID: 2648691
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.